An international conference on pediatrics held by Hebei Children's Hospital on November 13 brought together many well-known pediatric hematological tumor experts and scholars from China, and other countries like Canada and the U.S. Views were shared on treatment methods and experience of how to improve the survival rate of children suffering from malignant hematological tumor diseases.

　　Guo Yuming, deputy director of the Science and Technology Department of Hebei Province, also director of Hebei Provincial Bureau of Foreign Experts Affairs, stressed that Hebei Children's Hospital (HBCH) had been actively involved in cooperation with world-class medical research institutes.

　　Duan Guochen, the director of HBCH, spoke about the achievements made at the institution as well as its proposed development plan, while professor Ronald Grant, principal investigator of the pediatric oncology research center at the Hospital for Sick Children (SickKids) of Canada, summarized a variety of methods focusing on pediatric recurrent neuroblastoma, seen as an upfront therapy project. CAR-T cell immunotherapy and vaccination-based therapy may be forthcoming, which shed light on improving prognosis, reducing recurrence and mortality.

　　Michael Pulsipher, from the Transplantation and Cellular Therapy section of Los Angeles Children's Hospital, shared a report showing the latest research results supported by substantial scientific data and multi-center joint studies. He said the challenges faced by CAR-T cell therapy in predicting the recurrence of acute lymphoblastic leukemia, shows a meaningful direction for further exploration of cellular immunotherapy in the future.

　　Source: Hebei Chidren's Hospital